We claim:

1. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7 ± 0.2, 11.8 ± 0.2, and 13.3 ± 0.2.

2. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7 ± 0.2, 11.8 ± 0.2, 13.3 ± 0.2, and 14.8 ± 0.2.

3. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7 ± 0.2, 11.8 ± 0.2, 13.3 ± 0.2, 14.8 ± 0.2 and 21.7 ± 0.2.

4. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising Raman shift peaks (cm^{-1}) at 1625 ± 2, 1596 ± 2, and 1548 ± 2.

5. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising Raman shift peaks (cm^{-1}) at 1625 ± 2, 1616 ± 2, 1596 ± 2, and 1548 ± 2.

6. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has an infrared spectrum comprising infrared shift peaks (cm^{-1}) at 1581 ± 2, 1273 ± 2, 1010 ± 2, 906 ± 2 and 873 ± 2.

7. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a solid state NMR spectrum comprising ^{13}C chemical shifts (ppm) at 112.6 ± 0.2, 133.9 ± 0.2, and 171.5 ± 0.2.

8. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising a Raman shift peak (cm^{-1}) at 1625 cm ± 2; and a solid state NMR spectrum comprising a ^{13}C chemical shift (ppm) at 133.9 ± 0.2.

9. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising a Raman shift peak

(cm^{-1}) at 1625 cm ± 2; and a solid state NMR spectrum comprising a ^{13}C chemical shift (ppm) at 171.5 ± 0.2.

10. The crystalline form of any one of claims 1-9, wherein said form is non-hygroscopic and anhydrous.

11. The crystalline form of any one of claims 1-10, wherein said form is substantially pure.

12. A pharmaceutical composition comprising the crystalline form of any one of claims 1-11.

Claims:

1. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7 ± 0.2, 11.8 ± 0.2, and 13.3 ± 0.2.

2. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine as claimed in claim 1, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7 ± 0.2, 11.8 ± 0.2, 13.3 ± 0.2, and 14.8 ± 0.2.

3. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine as claimed in claim 1, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7 ± 0.2, 11.8 ± 0.2, 13.3 ± 0.2, 14.8 ± 0.2 and 21.7 ± 0.2.

4. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising Raman shift peaks (cm^{-1}) at 1625 ± 2, 1596 ± 2, and 1548 ± 2.

5. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine as claimed in claim 4, wherein said crystalline form has a Raman spectrum comprising Raman shift peaks (cm^{-1}) at 1625 ± 2, 1616 ± 2, 1596 ± 2, and 1548 ± 2.

6. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has an infrared spectrum comprising infrared shift peaks (cm^{-1}) at 1581 ± 2, 1273 ± 2, 1010 ± 2, 906 ± 2 and 873 ± 2.

7. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a solid state NMR spectrum comprising ^{13}C chemical shifts (ppm) at 112.6 ± 0.2, 133.9 ± 0.2, and 171.5 ± 0.2.

8. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising a Raman shift peak (cm^{-1}) at 1625 cm ± 2; and a solid state NMR spectrum comprising a ^{13}C chemical shift (ppm) at 133.9 ± 0.2.

9. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a Raman spectrum comprising a Raman shift peak

(cm^{-1}) at 1625 cm ± 2; and a solid state NMR spectrum comprising a ^{13}C chemical shift (ppm) at 171.5 ± 0.2.

10. The crystalline form of any one of claims 1-9, wherein said form is substantially pure.

11. A pharmaceutical composition comprising the crystalline form of any one of claims 1-10.